76003-30-0

Usage

Uses

Used in Pharmaceutical Industry:
2-METHYL-3-OXO-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER is used as a building block for the synthesis of various pharmaceuticals and organic compounds. Its unique chemical structure allows it to be incorporated into a wide range of molecules, contributing to the development of new drugs and therapeutic agents.
Used in Organic Chemistry:
2-METHYL-3-OXO-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER is used as a versatile reagent in organic chemistry for the synthesis of various organic compounds. Its ability to form stable intermediates and participate in a range of chemical reactions makes it a valuable tool for organic synthesis.
Used in Research and Development:
2-METHYL-3-OXO-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER is used as a research compound in the development of new chemical processes and methodologies. Its unique properties and reactivity make it an interesting subject for scientific investigation, potentially leading to new discoveries and applications in various fields.

InChI:InChI=1/C10H18N2O3/c1-7-8(13)11-5-6-12(7)9(14)15-10(2,3)4/h7H,5-6H2,1-4H3,(H,11,13)

Upstream product

• 76003-29-7 4-(t-butyloxycarbonyl)piperazin-2-one 
• 24424-99-5 di-tert-butyl dicarbonate 
• 23936-11-0 3-methylpiperazin-2-one 

Downstream Products

• 1338374-99-4 [1,1'-biphenyl]-4-yl-(8-methyl-3-(6-methylpyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone 

Relevant academic research and scientific papers

Selective NK-3 receptor antagonist, preparation and application thereof

The invention provides a selective NK-3 receptor antagonist, preparation and application thereof, particularly a compound represented by the following formula (I). The compound of the invention has unexpected activity to modulate cytokines and/or interferon, and is useful in the treatment of CNS and peripheral diseases or disorders.

N - acyl - [...] P 2X7 adjustment

The present invention is directed to compounds of Formula (I), which includes enantiomer and diasteromers thereof: These compounds are suitable for use in the treatment of diseases associated with P2X7 receptor activity such as diseases of the autoimmune

Novel methyl substituted 1-(5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanones are P2X7 antagonists

Abstract The optimization efforts that led to a novel series of methyl substituted 1-(5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanones that are potent rat and human P2X7 antagonists are described. These efforts resulted in the discovery of co

NOVEL CHIRAL N-ACYL-5,6,7,(8-SUBSTITUTED)-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR MEDIATED DISORDERS AND CHIRAL SYNTHESIS THEREOF

The present invention relates to novel compounds of Formula I and their use in therapeutic treatments. The invention further relates to a novel chiral synthesis of 5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines using N-sp3 protective groups. The invention also provides intermediates for use in the synthesis of compounds of Formula I.

HETEROCYCLIC COMPOUNDS

The invention is concerned with novel heterocyclyl compounds of formula (I) wherein A, X, Y, R3, R4, R5, R6, R7, R8, R9, R10, m and n are as herein defined, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and can be used as medicaments.

Alkylation of protected piperazinone dianions

A new method for the preparation of substituted piperazinones via alkylation of t-boc-piperazinone is presented.